Singapore markets close in 5 hours 2 minutes

CSL Limited (CSJ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
194.50-0.42 (-0.22%)
At close: 09:13AM CET
Full screen
Previous close194.92
Bid0.00 x 20000
Ask0.00 x 20000
Day's range194.50 - 194.50
52-week range152.30 - 205.95
Avg. volume12
Market cap93.791B
Beta (5Y monthly)0.16
PE ratio (TTM)41.92
EPS (TTM)4.64
Earnings dateN/A
Forward dividend & yield2.14 (1.09%)
Ex-dividend date06 Sept 2022
1y target estN/A
  • Motley Fool

    Why Shares of uniQure Rose 14.61% on Wednesday

    Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.

  • Zacks

    uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

    uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

  • Motley Fool

    Why Arcturus Therapeutics Stock Is Skyrocketing Today

    Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) are skyrocketing today, up by 26.5% as of 11:15 a.m. ET. The huge gain came after Arcturus announced yesterday that it has entered into a strategic collaboration with CSL Seqirus, a unit of CSL Limited (OTC: CSLL.Y). The two companies plan to work together to develop and market messenger RNA (mRNA) vaccines targeting COVID-19, flu, pandemic preparedness, and three other respiratory infectious diseases.